Arteriosclerosis

Arteriosclerosis is characterized especially by an accumulation of cholesterol containing fatty deposits (plaques) in the inner layers of the arteries. With increasing plaque volume the lumen of the arteries will decrease and the blood flow will be impaired.

In the context of arteriosclerosis, the functionality of the endothelial glycocalix (the inner layer of the arteries) is impaired and cannot perform efficient substance transfer anymore, which is required to support vascular protection and repair mechanisms. A targeted re-modelling of this glycocalix represents a new and promising treatment approach.

Arteriosclerosis, a silent and severe disease

Disease Number one, worldwide: arteriosclerosis!

The drug provided by PharmACT AG is named „BelACT®“ (A- Ateriosclerosis, C- Clean, T- Therapy) and will change the treatment of cardiovascular diseases on a worldwide basis.

Arteriosclerosis is characterized especially by an accumulation of cholesterol containing fatty deposits (plaques) in the inner layers of the arteries. With increasing plaque volume the lumen of the arteries will decrease and the blood flow will be impaired. If the coronary blood vessels (coronary arteries) are involved characteristic chest pain is his consequence (angina pectoris). Despite the relatively high success rates neither the balloon angioplasty nor the arterectomy or stents are perfect.

BelACT - Therapy of Arteriosclerosis by using a new medicine

Therapy with new pharmaceutical

In the context of atherosclerosis, the functionality of the endothelial glycocalix (the inner layer of the arteries) is impaired and cannot perform efficient substance transfer anymore, which is required to support vascular protection and repair mechanisms. A targeted re-modelling of this glycocalix represents a new and promising treatment approach.

During the timeframe of the last 10 years we could show, that the combination of pharmaceutical and treatment an abatement of arteriosklerosis allows. This patented combination is important part of the scale of benefits from PharmACT AG.

Read more: BelACT - Therapy of Arteriosclerosis...

BelACT - Our Therapy Concept

Therapy of arteriosclerosis with "BelACT"

The PharmACT AG has developed a medication and a therapeutical concept having the potential to change the treatment of cardiovascular diseases on a worldwide basis.

We have integrated our concept in our company name:  The outstanding ACT treatment comprises the disease, A – Arteriosclerosis, C – Clean, and T – Therapy.

Read more: BelACT - Our Therapy Concept

Therapy of arteriosclerosis with "BelACT"

BelACT – Our Therapy Concept

The PharmACT AG is providing and has developed a pharmaceutical with a therapeutical concept which has the potential changing the treatment of cardiovascular diseases on a worldwide basis.

We have integrated our concept in our company name:  The outstanding ACT treatment comprises the disease, A – Arteriosclerosis, C – Clean, and T – Therapy.

Cardiovascular diseases are the most common cause of death on a worldwide basis. In Germany alone, these amount to ca. 40,2% of all death cases annually. According to the Statistical Governmental Agency in Wiesbaden this corresponds to ca. 342.000 death cases in Germany.

This situation is very well reflected also in other nations, i.e. the USA. In the USA, in the year 2011, ca. 597.000 patients died from cardiovascular diseases and 129.000 from strokes.
The treatment with the new drug allows on one hand the prevention of the disease and supports on the other hand the healing process of arteriosclerosis in different stages.

 

BelACT - My experience with the therapy

A report on my new life after treatment with BelACT

My name is Heiner Leinfeld*1, I was born in 1949. In October 1992 I had my first myocardial infarction having been not properly treated in the hospital in Offenburg where I lived at that time so that I had to be transported several hours later by helicopter to the Benedikt Kreutz Rehabilitationszentrum for Cardiovascular Diseases. After several heart catheter examinations the cardiologists decided that I could encounter the so-called „classical“ therapy.

In August 2002, 10 years later I had my second myocardial infarction.

Read more: BelACT - My experience with the therapy